Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationTacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationPhase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
“[ 71] A similar pattern was noted among cardiac events where those with MASLD and fibrosis stages 3 and 4 had a 2.2 fold higher risk for a cardiac event compared to those with MASLD and fibrosis level F0-F2 and 1.35 fold higher risk for hypertension.”
BackgroundMethodInfluentialHepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“For example, persistent inflammation, as seen in untreated viral hepatitis or nonalcoholic fatty liver disease (NAFLD), promotes progressive ECM deposition over time, which is associated with long-term outcomes such as liver failure, hepatocellular carcinoma and mortality 2–4 .”
BackgroundChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
“%) in the placebo group (p=0·45), and a lower proportion experienced worsening of steatosis (one [2”
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Self-citationYounossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.006 · Cited by 416
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationTissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“In a prospective United States study of 1,773 participants with biopsy-confirmed MASLD from 2009 to 2019, participants were followed-up for a median of 4 years and monitored for the development of hepatic and extrahepatic complications 32 .”
Self-citationAjmera, V., Cepin, S., Tesfai, K., Hofflich, H., Cadman, K., Lopez, S., Madamba, E., Bettencourt, R., Richards, L., Behling, C., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.11.010 · Cited by 327
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationNatural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Lifestyle interventions in nonalcoholic fatty liver disease
Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00800-4 · Cited by 281
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Lee, H.-H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., & Kim, S. U. (2024) · Gut · doi:10.1136/gutjnl-2023-331003 · Cited by 254
“35 Further validation studies, preferably using biopsy or imaging findings or the Fibrosis-4 index, are required to demonstrate the risk of CVD conferred by liver fibrosis in individuals with MASLD and related SLD.”
MethodNon-alcoholic fatty liver disease: Definition and subtypes
Han, S. K., Baik, S. K., & Kim, M. Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0424 · Cited by 245
Le, P., Tatar, M., Dasarathy, S., Alkhouri, N., Herman, W. H., Taksler, G. B., Deshpande, A., Ye, W., Adekunle, O. A., McCullough, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54707 · Cited by 243
Self-citationPathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Natural history of metabolic dysfunction-associated steatotic liver disease
Lekakis, V., & Papatheodoridis, G. V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.11.005 · Cited by 233
Pipitone, R. M., Ciccioli, C., Infantino, G., La Mantia, C., Parisi, S., Tulone, A., Pennisi, G., Grimaudo, S., & Petta, S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221145549 · Cited by 233
Wattacheril, J. J., Abdelmalek, M. F., Lim, J. K., & Sanyal, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.013 · Cited by 236
Self-citationElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
“Individuals with clinically signi fi cant fi - brosis ( $ F2), especially those with type 2 diabetes, have a greater risk of cirrhosis with liver decompensation, HCC, liver transplantation, and all-cause mortality (69 – 72).”
Sanyal, A. J., Foucquier, J., Younossi, Z. M., Harrison, S. A., Newsome, P. N., Chan, W.-K., Yilmaz, Y., De Ledinghen, V., Costentin, C., Zheng, M.-H., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.034 · Cited by 219
“These goals were met by studies with the following objectives: (1) to develop and calibrate the Agile 3+ and 4 scores and establish their sensitivity and specificity for diagnosis of AF or cirrhosis, respectively; (2) to optimize cut-offs to maximize the specificity without clinically relevant loss of sensitivity, to…”
BackgroundResultSelf-citationNg, C. H., Lim, W. H., Hui Lim, G. E., Hao Tan, D. J., Syn, N., Muthiah, M. D., Huang, D. Q., & Loomba, R. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.014 · Cited by 217
Self-citationImpact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00141-3 · Cited by 214
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Western diets and chronic diseases
Adolph, T. E., & Tilg, H. (2024) · Nature Medicine · doi:10.1038/s41591-024-03165-6 · Cited by 191
“Perturbation of the gut microbiome has been reported for patients with nonalcoholic fatty liver disease and particularly liver fibrosis 177,178 , a key determinant of patient outcome 179 , which could be therapeutically exploited in the future 167”
Mak, L.-Y., Liu, K., Chirapongsathorn, S., Yew, K. C., Tamaki, N., Rajaram, R. B., Panlilio, M. T., Lui, R., Lee, H. W., Lai, J. C.-T., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00967-4 · Cited by 182
“More than half of the global population living with MASLD is in the Asia-Pacific region, but paradoxically, there has been an under-representation of this population in natural history studies 169 and drug trials 170 .”
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00818-8 · Cited by 189
“Similarly, in a prospective study of 1,773 adults with biopsy-proven NAFLD, the incidence of HCC over 4 years was lower in stage 0–2 fibrosis (0.04 per 100 person-years) than in stage 3 (0.34 per 100 person-years) and stage 4 (0.14 per 100 person-years) 78 .”
BackgroundInfluentialSelf-citationHuang, D. Q., Noureddin, N., Ajmera, V., Amangurbanova, M., Bettencourt, R., Truong, E., Gidener, T., Siddiqi, H., Majzoub, A. M., Nayfeh, T., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00157-7 · Cited by 184
“We identified potential confounders based on previous reports in the literature 36-40 and selected a minimally sufficient set of confounders using a causal-directed acyclic graph (appendix p 20).”
Self-citationHuang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.025 · Cited by 190
Self-citationTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“Of the three main features of MASH — steatosis, inflammation and fibrosis — the development of advanced fibrosis is most closely associated with morbidity and mortality 69 .”
Sanyal, A. J., Lopez, P., Lawitz, E. J., Lucas, K. J., Loeffler, J., Kim, W., Goh, G. B. B., Huang, J.-F., Serra, C., Andreone, P., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02200-8 · Cited by 177
Self-citationSerra-Burriel, M., Juanola, A., Serra-Burriel, F., Thiele, M., Graupera, I., Pose, E., Pera, G., Grgurevic, I., Caballeria, L., Piano, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01174-1 · Cited by 171
Steatotic liver disease, MASLD and risk of chronic kidney disease
Bilson, J., Mantovani, A., Byrne, C. D., & Targher, G. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101506 · Cited by 166
“This finding has also been further corroborated by some cohort studies of patients with biopsy-proven NASH and liver fibrosis [31].”
ECM formation and degradation during fibrosis, repair, and regeneration
Mayorca-Guiliani, A. E., Leeming, D. J., Henriksen, K., Mortensen, J. H., Nielsen, S. H., Anstee, Q. M., Sanyal, A. J., Karsdal, M. A., & Schuppan, D. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00063-4 · Cited by 176
“Before developing cirrhosis, MASLD patients die of cardiovascular disease and extrahepatic cancer with more frequency than from a liver-related event 274,275 (Fig.”
Self-citationElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 252
Tincopa, M. A., & Loomba, R. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00066-3 · Cited by 160
Self-citationFerraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.013 · Cited by 192
“Once MASLD is diagnosed, the key question to be answered from a liver perspective regards the presence and severity of fi brosis, which is the major factor associated with the occurrence of liver outcomes [62].”
BackgroundNoninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Self-citationHarrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00017-6 · Cited by 142
Jamialahmadi, O., Vincentis, A. D., Tavaglione, F., Malvestiti, F., Li‐Gao, R., Mancina, R. M., Alvarez, M., Gelev, K. Z., Maurotti, S., Gentilucci, U. V., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03284-0 · Cited by 174
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Rinella, M. E., Chalasani, N., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C. A., Burch, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502242 · Cited by 163
Self-citationHepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
Thomas, J. A., Kendall, B. J., El‐Serag, H. B., Thrift, A. P., & Macdonald, G. A. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00275-3 · Cited by 155
Ajmera, V., Kim, B. K., Yang, K., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idilman, R., Gumussoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 138
Self-citationSanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137
Self-citationA global research priority agenda to advance public health responses to fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Arrese, M. A., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.035 · Cited by 149
Castera, L., Laouenan, C., Vallet-Pichard, A., Vidal-Trécan, T., Manchon, P., Paradis, V., Roulot, D., Gault, N., Boitard, C., Terris, B., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2048 · Cited by 136
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Sanyal, A. J., Shankar, S. S., Yates, K. P., Bolognese, J., Daly, E., Dehn, C. A., Neuschwander-Tetri, B., Kowdley, K., Vuppalanchi, R., Behling, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02539-6 · Cited by 131
Self-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Tincopa, M. A., Anstee, Q. M., & Loomba, R. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.011 · Cited by 126
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Self-citationNon‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 160
Anstee, Q. M., Berentzen, T. L., Nitze, L. M., Jara, M., Jensen, A. B., Kjær, M. S., Mangla, K. K., Tarp, J. M., & Khunti, K. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100780 · Cited by 168
Risk stratification and early detection biomarkers for precision HCC screening
Lee, Y., Fujiwara, N., Yang, J. D., & Hoshida, Y. (2022) · Hepatology · doi:10.1002/hep.32779 · Cited by 147
Nogueira, J. P., & Cusi, K. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 110
“Finally, in a prospective study involving individuals with biopsy-proven NASH, all-cause mortality increased with increasing fi brosis stages (65).”
BackgroundMetabolic dysfunction-associated steatotic liver disease and the heart
Driessen, S., Francque, S., Anker, S. D., Cabezas, M. C., Grobbee, D. E., Tushuizen, M. E., & Holleboom, A. G. (2023) · Hepatology · doi:10.1097/hep.0000000000000735 · Cited by 151
“[27] In this study, the presence of MASH was not associated with a higher incidence of asCVD events, although a trend was apparent.”
Sripongpun, P., Kim, W. R., Mannalithara, A., Charu, V., Vidovszky, A. A., Asch, S. M., Desai, M., Kim, S. H., & Kwong, A. J. (2022) · Hepatology · doi:10.1002/hep.32545 · Cited by 143
“[22] Finally, most of the subjects with NAFLD included in this study had abnormal (>25 kg/m2) BMI, including over 90% of the trial subjects and over 75% of NHANES III participants with NAFLD.”
BackgroundInfluentialMolecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Fujiwara, N., Kubota, N., Crouchet, É., Koneru, B., Marquez, C. A., Jajoriya, A. K., Panda, G., Qian, T., Zhu, S., Goossens, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4474 · Cited by 138
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
Allen, A. M., Therneau, T. M., Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Canning, R. E., Benson, J. T., & Kamath, P. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.004 · Cited by 121
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Yip, T. C., Vilar‐Gomez, E., Petta, S., Yilmaz, Y., Wong, G. L., Adams, L. A., de Lédinghen, V., Sookoian, S., & Wong, V. W. (2023) · Hepatology · doi:10.1002/hep.32774 · Cited by 123
“Mortality and liver‐related events, including hepatic decompensation and HCC, significantly increased in a dose‐dependent manner with increasing fibrosis stages; stage 3 or 4 fibrosis displayed the highest rates.[12] This study also reported that nearly 14% of patients with stage F0 to F2 fibrosis had progression to s…”
BackgroundLoomba, R. S., Bédossa, P., Grimmer, K., Kemble, G. W., Martins, E. B., McCulloch, W. F., O’Farrell, M., Tsai, W.-W., Cobiella, J., Lawitz, E., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00246-2 · Cited by 126
Self-citationGuillot, A., Winkler, M., Silva Afonso, M., Aggarwal, A., Lopez, D., Berger, H., Kohlhepp, M. S., Liu, H., Özdirik, B., Eschrich, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000270 · Cited by 116
“NAFLD is the most prevalent liver disease and may evolve to NASH and ultimately, to HCC.[1] The current trends clearly show that the burden of NAFLD on global health is increasing at a fast pace.”
BackgroundEskridge, W., Cryer, D. R., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196216 · Cited by 111
“A prospective multicenter study estimated the incidence rate of deaths from any cause at 0.32 deaths per 100 person-years for stage F0–F2, rising to 0.89 deaths per 100 persons-years for stage F3 and 1.76 deaths per 100 person-years for stage F4 in patients with MASLD [29].”
InfluentialSelf-citationSavage, T. M., Fortson, K. T., de los Santos-Alexis, K., Oliveras-Alsina, A., Rouanne, M., Rae, S. S., Gamarra, J. R., Shayya, H., Kornberg, A., Cavero, R., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.009 · Cited by 120
Noninvasive Assessment of Liver Fibrosis
Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 147
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Mantovani, A., Byrne, C. D., Benfari, G., Bonapace, S., Simon, T. G., & Targher, G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.007 · Cited by 114
Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155642 · Cited by 113
Abdelmalek, M. F., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Lawitz, E. J., Harrison, S. A., Jacobson, I. M., Imajo, K., Gunn, N., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.012 · Cited by 110
Self-citationMetabolic dysfunction-associated steatotic liver disease and its link to cancer
Kalligeros, M., Henry, L. L., & Younossi, Z. M. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156004 · Cited by 133
Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Loomba, R., Sanyal, A. J., Nakajima, A., Neuschwander-Tetri, B. A., Goodman, Z. D., Harrison, S. A., Lawitz, E. J., Gunn, N., Imajo, K., Ravendhran, N., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.011 · Cited by 110
Self-citationHepatic stellate cells control liver zonation, size and functions via R-spondin 3
Sugimoto, A., Saito, Y., Wang, G., Sun, Q., Yin, C., Lee, K. H., Geng, Y., Rajbhandari, P., Hernandez, C., Steffani, M., et al. (2025) · Nature · doi:10.1038/s41586-025-08677-w · Cited by 133
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327777 · Cited by 110
Self-citationCao, L., An, Y., Zhao, Z., Liu, H., Jiang, J., Liu, W., Zhou, Y., Shi, M., Dai, W., Lv, Y., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03315-0 · Cited by 133
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 136
“33 .”
Kotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.037 · Cited by 108
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“These results are very encouraging, considering that three in four people with obesity 123 and one in two people with T2DM 124 have MASLD and are at high risk of progression to MASH, cirrhosis and hepatocellular carcinoma 125 .”
Lei, Y., Tang, L., Chen, Q., Wu, L., He, W., Tu, D., Wang, S., Chen, Y., Liu, S., Xie, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34671-1 · Cited by 104
O’Farrell, M., Duke, G., Crowley, R., Buckley, D., Martins, E. B., Bhattacharya, D., Friedman, S. L., & Kemble, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19459-z · Cited by 105
“Histological scoring of H&E stained liver slides using a scale from normal (0) to severe (4) based on overall hepatic changes showed that TVB-3664 treatment was associated with a dose-dependent reduction in liver histology severity score (Fig.”
Mederacke, I., Filliol, A., Affo, S., Nair, A., Hernandez, C., Sun, Q., Hamberger, F., Brundu, F., Chen, Y., Ravichandra, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abe5795 · Cited by 103
Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W.-S., Younes, Z. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000607 · Cited by 94
“[2] This is a vexing issue in pivotal trial design where the selection of patients with disease that may still be responsive to therapeutic intervention needs to be balanced with the regulatory requirement to show a positive impact on clinical outcomes, which would require a very large long-term…”
Self-citationCurrent and emerging strategies for the prevention of hepatocellular carcinoma
Yeo, Y. H., Abdelmalek, M. F., Khan, S. A., Moylan, C. A., Rodriquez, L. M., Villanueva, A., & Yang, J. D. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01021-z · Cited by 111
“The association between advanced fibrosis and increased HCC risk is well-supported by both preclinical translational and prospective cohort studies 118,119 .”
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“Accordingly, fi brosis represents a signi fi cant risk factor for the development of HCC in patients [261].”
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.